These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30268457)

  • 1. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
    Zhang XC; Zhang J; Li M; Huang XS; Yang XN; Zhong WZ; Xie L; Zhang L; Zhou M; Gavine P; Su X; Zheng L; Zhu G; Zhan P; Ji Q; Wu YL
    J Transl Med; 2013 Jul; 11():168. PubMed ID: 23842453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
    BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
    Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
    Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.
    Gandara DR; Mack PC; Bult C; Li T; Lara PN; Riess JW; Astrow SH; Gandour-Edwards R; Cooke DT; Yoneda KY; Moore EH; Pan CX; Burich RA; David EA; Keck JG; Airhart S; Goodwin N; de Vere White RW; Liu ET
    Clin Lung Cancer; 2015 May; 16(3):165-72. PubMed ID: 25838158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
    Kang HN; Kim JH; Park AY; Choi JW; Lim SM; Kim J; Shin EJ; Hong MH; Pyo KH; Yun MR; Kim DH; Lee H; Yoon SO; Kim DH; Park YM; Byeon HK; Jung I; Paik S; Koh YW; Cho BC; Kim HR
    BMC Cancer; 2020 Apr; 20(1):316. PubMed ID: 32293356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk J; Rolff J; Becker M; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
    Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
    Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
    Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
    Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration.
    Fuchs V; Sobarzo A; Msamra M; Kezerle Y; Linde L; Sevillya G; Anoze A; Refaely Y; Cohen AY; Melamed I; Azriel A; Shoukrun R; Raviv Y; Porgador A; Peled N; Roisman LC
    Clin Transl Oncol; 2024 Sep; 26(9):2227-2239. PubMed ID: 38553659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer.
    Woo XY; Srivastava A; Mack PC; Graber JH; Sanderson BJ; Lloyd MW; Chen M; Domanskyi S; Gandour-Edwards R; Tsai RA; Keck J; Cheng M; Bundy M; Jocoy EL; Riess JW; Holland W; Grubb SC; Peterson JG; Stafford GA; Paisie C; Neuhauser SB; Karuturi RKM; George J; Simons AK; Chavaree M; Tepper CG; Goodwin N; Airhart SD; Lara PN; Openshaw TH; Liu ET; Gandara DR; Bult CJ
    Cancer Res; 2022 Nov; 82(22):4126-4138. PubMed ID: 36069866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.
    John T; Kohler D; Pintilie M; Yanagawa N; Pham NA; Li M; Panchal D; Hui F; Meng F; Shepherd FA; Tsao MS
    Clin Cancer Res; 2011 Jan; 17(1):134-41. PubMed ID: 21081655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.